Equity Profile

RGC

Regencell Bioscience Holdings Limited

Health CarePharmaceuticals$9.9B

Jun27Thu

Pre-Earnings Brief

UpcomingQ4-2017After Close5:00 PM EDT

Company Snapshot

Regencell Bioscience Holdings Limited operates in the healthcare sector, specifically in pharmaceuticals. The company focuses on developing innovative treatments, which is crucial as the demand for effective healthcare solutions continues to grow.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and attract more customers.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RGC Q4-2017 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-3.97%

Avg Stock Reaction

+0.00%

Last Quarter Recap

In the last quarter, Regencell reported an EPS of $0.07, falling short of expectations by 36%. This trend of missing estimates has raised concerns among investors.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Regencell's upcoming earnings report are mixed, given its recent performance and lack of analyst estimates.

Bull Case

If Regencell can surprise investors with better-than-expected EPS and revenue growth, it could signal a turnaround and boost investor confidence.

Bear Case

Conversely, if the company continues to miss estimates, it may further erode trust and lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for this quarter?

Given the company's recent history of missing EPS estimates, this number will be crucial in determining investor sentiment.

What is the outlook for R&D spending moving forward?

Investors will want to know if the company plans to increase its investment in R&D, as this could impact future product development and revenue.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Regencell to rebound from its recent earnings misses, as the company's focus on innovative treatments could lead to unexpected positive results.

Supporting Evidence

The options market is pricing in an 11.9% move, indicating that traders expect significant volatility, which could favor a positive surprise.

Historical data shows that the stock has reacted positively to unexpected earnings beats, suggesting potential upside.

Key Risk

If the EPS comes in above $0.15, it could significantly shift market sentiment and challenge the current bearish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Regencell can turn around its recent performance and regain investor confidence.

Bull Confirmed If

An EPS of $0.15 or higher would confirm the bull case and indicate a potential recovery in profitability.

Bear Confirmed If

An EPS below $0.05 would confirm the bear case, suggesting ongoing challenges in achieving profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±11.9%

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Detail

ATM IV

1.4%

30d HV

69.6%

Calls (5K)P/C Ratio: 0.02Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Regencell beats expectations, history suggests a positive reaction, potentially leading to an average 1-day move of around 3.6%.

In-Line / Cautious

A cautious in-line report may lead to muted reactions, as investors weigh the company's future prospects against its recent performance.

Miss

If the company misses expectations again, history suggests a negative reaction, with an average 1-day move of around -1.3%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or clinical trials.
2Details on cost management and operational efficiency improvements.
3Insights into market demand for Regencell's products.
4Management's commentary on competitive positioning in the pharmaceutical sector.
5Guidance on future revenue expectations and growth strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jun25

SNXReported

TD SYNNEX Corporation

RecapView

Jun25

CUKReported

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and attract more customers.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RGC Q4-2017 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-3.97%

Avg Stock Reaction

+0.00%

Last Quarter Recap

In the last quarter, Regencell reported an EPS of $0.07, falling short of expectations by 36%. This trend of missing estimates has raised concerns among investors.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Regencell's upcoming earnings report are mixed, given its recent performance and lack of analyst estimates.

Bull Case

If Regencell can surprise investors with better-than-expected EPS and revenue growth, it could signal a turnaround and boost investor confidence.

Bear Case

Conversely, if the company continues to miss estimates, it may further erode trust and lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for this quarter?

Given the company's recent history of missing EPS estimates, this number will be crucial in determining investor sentiment.

What is the outlook for R&D spending moving forward?

Investors will want to know if the company plans to increase its investment in R&D, as this could impact future product development and revenue.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Regencell to rebound from its recent earnings misses, as the company's focus on innovative treatments could lead to unexpected positive results.

Supporting Evidence

The options market is pricing in an 11.9% move, indicating that traders expect significant volatility, which could favor a positive surprise.

Historical data shows that the stock has reacted positively to unexpected earnings beats, suggesting potential upside.

Key Risk

If the EPS comes in above $0.15, it could significantly shift market sentiment and challenge the current bearish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Regencell can turn around its recent performance and regain investor confidence.

Bull Confirmed If

An EPS of $0.15 or higher would confirm the bull case and indicate a potential recovery in profitability.

Bear Confirmed If

An EPS below $0.05 would confirm the bear case, suggesting ongoing challenges in achieving profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±11.9%

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Detail

ATM IV

1.4%

30d HV

69.6%

Calls (5K)P/C Ratio: 0.02Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Regencell beats expectations, history suggests a positive reaction, potentially leading to an average 1-day move of around 3.6%.

In-Line / Cautious

A cautious in-line report may lead to muted reactions, as investors weigh the company's future prospects against its recent performance.

Miss

If the company misses expectations again, history suggests a negative reaction, with an average 1-day move of around -1.3%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or clinical trials.
2Details on cost management and operational efficiency improvements.
3Insights into market demand for Regencell's products.
4Management's commentary on competitive positioning in the pharmaceutical sector.
5Guidance on future revenue expectations and growth strategies.